What Is Atosiban?

Indications: For pregnant women over 18 years of age, 24 to 33 weeks gestational age, normal fetal heart rate, in regular contractions of 4 or more times every 30 minutes, each lasting at least 30 seconds, with cervical dilation of 1 to 3 cm (Primary babies 0 to 3 cm), when the cervix disappears by more than 50%, the imminent premature birth is postponed.

Atosiban

Right!

Indications: For pregnant women over 18 years of age, 24 to 33 weeks gestational age, normal fetal heart rate, in regular contractions of 4 or more times every 30 minutes, each lasting at least 30 seconds, with cervical dilation of 1 to 3 cm (Primary babies 0 to 3 cm), when the cervix disappears by more than 50%, the imminent premature birth is postponed.

Chinese name

Atosiban

Foreign name

Atosiban

CAS

90779-69-4

Molecular weight

994.1886

Chinese name:

Dosage: The initial dose is 6.75mg, which is administered by injection with 7.5mg / ml injection of this product; then concentrated with 7.5mg / ml of this product for 3 hours in large doses (300g per minute) infusion; then 7.5mg of this product The mg / ml concentrate is infused at a low dose (100 g per minute) for up to 45 hours. Continuous treatment should not exceed 48 hours. During the whole course of treatment, the total dose should not exceed 330mg. Treatment should begin as soon as possible after the diagnosis of preterm birth.

Adverse reactions: No

Note: This product is contraindicated in the following pregnant women: those with a gestational age of less than 24 weeks or more than 33 weeks, those with a premature rupture of the membranes greater than 30 weeks, those with intrauterine fetal growth retardation and abnormal fetal heart rate. Childbirth, eclampsia and severe preeclampsia who must give birth, intrauterine fetal death, suspicious intrauterine infection, placenta previa, placenta separation, those who continue to be pregnant are at risk to the mother or fetus, known to this product Allergic to active ingredients or excipients. When the use of patients with premature rupture of membranes cannot be ruled out, the benefits of delayed delivery and the risk of potential chorioamnionitis should be weighed. The efficacy of this product for multiple pregnancy or gestational age between 24 and 27 weeks has not been determined. Contractions and fetal heart rate should be monitored at the time of administration, continuous contractions should be considered, and postpartum blood loss should be monitored. There are fewer cases of overuse, and no abnormal symptoms have been reported. The most common adverse reaction (incidence greater than 10%) was nausea. Common (incidence rates of 1% to 10%) are headache, dizziness, flushing, vomiting, palpitations, hypotension, injection site reactions, and hyperglycemia. Rare (incidence rate: 0.1% to 1%) are fever, insomnia, pruritus, and rash.